Edwards Lifesciences (EW)Officer sold ~$205K

~$205K

Approx. value · 2,500 sh @ $81.95

31K

Holds after · shares reported

Traded

Aug 25, 2025

Filed

Aug 25, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jul 23, 2025FDAFDA device clearance: HemoSphere Advanced Monitor (HEM1); HemoSphere Technology Module (HEMTOM10); HemoSphere ClearSight Module (HEMCSM10); Smart Pressure Controller (PC1Q); Acumen…
2. Jul 28, 2025InsiderOfficer sold ~$327K of EW shares in the open market
3. Aug 18, 2025InsiderOfficer sold ~$699K of EW shares in the open market
4. Aug 25, 2025 · this disclosureInsiderOfficer sold ~$205K of EW shares in the open market

What came next

1. Aug 29, 2025FDAFDA device clearance: Edwards eSheath Optima introducer set
2. Sep 17, 2025FDAFDA device clearance: Carpentier-Edwards Physio Annuloplasty Ring (4450)
3. Sep 23, 2025FDAFDA device clearance: Edwards MC3 Tricuspid annuloplasty ring (4900)
4. Oct 17, 20255% stakeBlackRock, Inc. reported a passive stake (13G) of 7.5%
5. Oct 21, 2025FDAFDA device clearance: HemoSphere Stream Module
6. Oct 30, 2025Company filing · Form 8-K · ResultsReported its results
7. Oct 30, 2025Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On October 30, 2025, Scott Ullem, the Chief Financial Officer of Edwards Lifesciences Corporation, a Delaware corporation (the “Corporation”), informed the Corporation of his decision to transition from his role by mid-year 2026.”
8. Nov 10, 2025Insider · 2 peopleInsiders: 3 sales (~$1.2M)
9. Dec 8, 2025Insider · 2 peopleInsiders: 2 sales (~$1.9M)
10. Dec 9, 2025InsiderCFO sold ~$650K of EW shares in the open market
11. Dec 10, 2025Insider · 2 peopleInsiders: 2 sales (~$1.3M)
12. Dec 11, 2025InsiderOfficer sold ~$169K of EW shares in the open market
13. Dec 12, 2025Insider · 3 peopleInsiders: 4 sales (~$1.3M)
14. Dec 18, 2025FDAFDA device clearance: HemoSphere Alta Advanced Monitoring Platform (ALTAALL1; ALTACR1; ALTASR1)
15. Dec 22, 2025FDAFDA device approval: SAPIEN M3 Transcatheter Mitral Valve Replacement System

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Edwards Lifesciences

For Edwards Lifesciences, OQRO holds 11 insider filings (SEC Form 4 or Form 144), 1 Congress trade report and 21 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its EW page.

Other recent filings by Daveen Chopra, CVP, TMTT

• SEC Form 4 at Edwards Lifesciences (EW)Aug 26, 2026
• SEC Form 4 at Edwards Lifesciences (EW)Aug 26, 2026
• SEC Form 4 at Edwards Lifesciences (EW)May 22, 2026
• SEC Form 4 at Edwards Lifesciences (EW)Dec 11, 2025
• SEC Form 4 at Edwards Lifesciences (EW)May 22, 2025

The full history of Daveen Chopra, CVP, TMTT is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Edwards Lifesciences

• SEC Form 4Oct 8, 2026
• SEC Form 4Sep 11, 2026
• SEC Form 4Aug 31, 2026
• SEC Form 4Aug 28, 2026
• SEC Form 4Aug 26, 2026
• SEC Form 4Aug 26, 2026

Everything OQRO holds on this company is on its EW page.